[144] Arrowhead Research Corporation SEC Filing
Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc., filed a Form 144 notice indicating a proposed sale of 9,265,312 shares of common stock of the issuer through Jefferies LLC on Nasdaq. The filing reports an aggregate market value of $185,213,586.88 and lists total shares outstanding as 138,257,550. The approximate date of sale is 08/13/2025.
The filing states these securities were acquired in a private placement from the issuer on 02/07/2025 by Sarepta Therapeutics Investments, Inc., with 11,926,301 shares acquired and payment made in cash on that date. The notice includes the standard representation that the person for whose account the securities are to be sold does not know of any undisclosed material adverse information.
Sarepta Therapeutics Investments, Inc., controllata al 100% di Sarepta Therapeutics, Inc., ha presentato un avviso Form 144 indicando la vendita proposta di 9,265,312 azioni ordinarie dell'emittente tramite Jefferies LLC sul Nasdaq. La comunicazione riporta un aggregate market value di $185,213,586.88 e indica il totale delle azioni in circolazione pari a 138,257,550. La data approssimativa della vendita 猫 08/13/2025.
Il deposito dichiara che questi titoli sono stati acquisiti in un collocamento privato dall'emittente in data 02/07/2025 da Sarepta Therapeutics Investments, Inc., con l'acquisto di 11,926,301 azioni e pagamento in contanti in quella data. L'avviso include la dichiarazione standard secondo cui la persona per conto della quale i titoli saranno venduti non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Sarepta Therapeutics Investments, Inc., filial de propiedad total de Sarepta Therapeutics, Inc., present贸 un aviso Form 144 indicando una venta propuesta de 9,265,312 acciones ordinarias del emisor a trav茅s de Jefferies LLC en Nasdaq. La presentaci贸n informa un aggregate market value de $185,213,586.88 y enumera el total de acciones en circulaci贸n como 138,257,550. La fecha aproximada de la venta es 08/13/2025.
La presentaci贸n indica que estos valores fueron adquiridos en una colocaci贸n privada por el emisor el 02/07/2025 por Sarepta Therapeutics Investments, Inc., con 11,926,301 acciones adquiridas y pago en efectivo en esa fecha. El aviso incluye la representaci贸n est谩ndar de que la persona en cuyo nombre se vender谩n los valores no conoce ninguna informaci贸n material adversa no divulgada.
Sarepta Therapeutics Investments, Inc.鞚� Sarepta Therapeutics, Inc.鞚� 鞝勳暋 於滌瀽 鞛愴殞靷靹� Form 144 瓿奠嫓毳� 鞝滌稖頃橃棳 Nasdaq鞚� 韱淀暣 Jefferies LLC鞐愳劀 氚滍枆須岇偓鞚� 氤错喌欤� 9,265,312欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 鞁犼碃頄堨姷雼堧嫟. 瓿奠嫓鞐愲姅 aggregate market value $185,213,586.88臧� 氤搓碃霅橃柎 鞛堦碃 齑� 氚滍枆欤检嫕靾橂姅 138,257,550欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 毵る弰 鞓堨爼鞚检潃 08/13/2025搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
瓿奠嫓鞐愲姅 鞚� 歃濌秾霌れ澊 氚滍枆鞛愲攵�韯� 02/07/2025鞐� 靷爜 氚办爼(private placement)鞙茧 旆摑霅橃棃瓿� Sarepta Therapeutics Investments, Inc.臧� 11,926,301欤茧ゼ 頃措嫻鞚检棎 順勱笀鞙茧 雽�旮� 歆�旮夗晿鞐� 旆摑頄堧嫟瓿� 鞝侅嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 韱奠鞐愲姅 歃濌秾鞚� 韺愲Г頃� 瓿勳爼鞚� 靷瀸鞚� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Sarepta Therapeutics Investments, Inc., filiale en propri茅t茅 exclusive de Sarepta Therapeutics, Inc., a d茅pos茅 une notification Form 144 indiquant la vente propos茅e de 9,265,312 actions ordinaires de l'茅metteur par l'interm茅diaire de Jefferies LLC sur le Nasdaq. Le dossier fait 茅tat d'une aggregate market value de $185,213,586.88 et indique le nombre total d'actions en circulation 脿 138,257,550. La date approximative de la vente est le 08/13/2025.
Le dossier indique que ces titres ont 茅t茅 acquis lors d'un placement priv茅 aupr猫s de l'茅metteur le 02/07/2025 par Sarepta Therapeutics Investments, Inc., qui a achet茅 11,926,301 actions et a r茅gl茅 en esp猫ces 脿 cette date. La notification comprend la d茅claration standard selon laquelle la personne pour le compte de laquelle les titres doivent 锚tre vendus ne conna卯t aucune information d茅favorable importante non divulgu茅e.
Sarepta Therapeutics Investments, Inc., eine hundertprozentige Tochtergesellschaft von Sarepta Therapeutics, Inc., hat eine Form-144-Mitteilung eingereicht, die einen geplanten Verkauf von 9,265,312 Stammaktien des Emittenten 眉ber Jefferies LLC an der Nasdaq ank眉ndigt. Die Einreichung nennt einen aggregate market value von $185,213,586.88 und gibt die insgesamt ausstehenden Aktien mit 138,257,550 an. Das voraussichtliche Verkaufsdatum ist 08/13/2025.
Die Mitteilung besagt, dass diese Wertpapiere am 02/07/2025 durch eine Privatplatzierung vom Emittenten erworben wurden, wobei Sarepta Therapeutics Investments, Inc. 11,926,301 Aktien erworben und den Kauf an diesem Datum bar bezahlt hat. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass die Person, in deren Auftrag die Wertpapiere verkauft werden sollen, keine nicht offengelegten, wesentlichen nachteiligen Informationen kennt.
- Brokered sale through Jefferies LLC on Nasdaq indicates the transaction is being facilitated by a registered broker.
- Securities were acquired in a private placement and paid in cash on 02/07/2025, with acquisition details disclosed in the filing.
- Proposed sale of 9,265,312 shares with an aggregate market value of $185,213,586.88 is sizable relative to the companys reported shares outstanding (138,257,550).
- 11,926,301 shares were acquired in the private placement on 02/07/2025, indicating the filing relates to a substantial block of recently issued securities.
Insights
TL;DR: Large Rule 144 notice filed for 9.27M ARWR shares (about $185.2M), to be sold via Jefferies on Nasdaq on 08/13/2025.
The Form 144 documents a proposed sale of 9,265,312 shares with an aggregate market value of $185,213,586.88, to be executed through Jefferies LLC on Nasdaq. The securities were acquired in a private placement on 02/07/2025 and paid for in cash. This filing provides the required regulatory disclosure under Rule 144 and notifies the market of an intended secondary sale. The notice also confirms the filer represents no undisclosed material adverse information.
TL;DR: Disclosure shows compliance with Rule 144 procedures for a sizeable sale by a Sarepta subsidiary; broker and acquisition details are documented.
The filing identifies Jefferies LLC as the broker and records the acquisition source as the issuer via a private placement on 02/07/2025, with 11,926,301 shares acquired by Sarepta Therapeutics Investments, Inc. The Form 144 includes the customary attestation regarding material adverse information, indicating the seller is meeting Form 144 disclosure requirements for an intended sale on 08/13/2025.
Sarepta Therapeutics Investments, Inc., controllata al 100% di Sarepta Therapeutics, Inc., ha presentato un avviso Form 144 indicando la vendita proposta di 9,265,312 azioni ordinarie dell'emittente tramite Jefferies LLC sul Nasdaq. La comunicazione riporta un aggregate market value di $185,213,586.88 e indica il totale delle azioni in circolazione pari a 138,257,550. La data approssimativa della vendita 猫 08/13/2025.
Il deposito dichiara che questi titoli sono stati acquisiti in un collocamento privato dall'emittente in data 02/07/2025 da Sarepta Therapeutics Investments, Inc., con l'acquisto di 11,926,301 azioni e pagamento in contanti in quella data. L'avviso include la dichiarazione standard secondo cui la persona per conto della quale i titoli saranno venduti non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Sarepta Therapeutics Investments, Inc., filial de propiedad total de Sarepta Therapeutics, Inc., present贸 un aviso Form 144 indicando una venta propuesta de 9,265,312 acciones ordinarias del emisor a trav茅s de Jefferies LLC en Nasdaq. La presentaci贸n informa un aggregate market value de $185,213,586.88 y enumera el total de acciones en circulaci贸n como 138,257,550. La fecha aproximada de la venta es 08/13/2025.
La presentaci贸n indica que estos valores fueron adquiridos en una colocaci贸n privada por el emisor el 02/07/2025 por Sarepta Therapeutics Investments, Inc., con 11,926,301 acciones adquiridas y pago en efectivo en esa fecha. El aviso incluye la representaci贸n est谩ndar de que la persona en cuyo nombre se vender谩n los valores no conoce ninguna informaci贸n material adversa no divulgada.
Sarepta Therapeutics Investments, Inc.鞚� Sarepta Therapeutics, Inc.鞚� 鞝勳暋 於滌瀽 鞛愴殞靷靹� Form 144 瓿奠嫓毳� 鞝滌稖頃橃棳 Nasdaq鞚� 韱淀暣 Jefferies LLC鞐愳劀 氚滍枆須岇偓鞚� 氤错喌欤� 9,265,312欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 鞁犼碃頄堨姷雼堧嫟. 瓿奠嫓鞐愲姅 aggregate market value $185,213,586.88臧� 氤搓碃霅橃柎 鞛堦碃 齑� 氚滍枆欤检嫕靾橂姅 138,257,550欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 毵る弰 鞓堨爼鞚检潃 08/13/2025搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
瓿奠嫓鞐愲姅 鞚� 歃濌秾霌れ澊 氚滍枆鞛愲攵�韯� 02/07/2025鞐� 靷爜 氚办爼(private placement)鞙茧 旆摑霅橃棃瓿� Sarepta Therapeutics Investments, Inc.臧� 11,926,301欤茧ゼ 頃措嫻鞚检棎 順勱笀鞙茧 雽�旮� 歆�旮夗晿鞐� 旆摑頄堧嫟瓿� 鞝侅嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 韱奠鞐愲姅 歃濌秾鞚� 韺愲Г頃� 瓿勳爼鞚� 靷瀸鞚� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Sarepta Therapeutics Investments, Inc., filiale en propri茅t茅 exclusive de Sarepta Therapeutics, Inc., a d茅pos茅 une notification Form 144 indiquant la vente propos茅e de 9,265,312 actions ordinaires de l'茅metteur par l'interm茅diaire de Jefferies LLC sur le Nasdaq. Le dossier fait 茅tat d'une aggregate market value de $185,213,586.88 et indique le nombre total d'actions en circulation 脿 138,257,550. La date approximative de la vente est le 08/13/2025.
Le dossier indique que ces titres ont 茅t茅 acquis lors d'un placement priv茅 aupr猫s de l'茅metteur le 02/07/2025 par Sarepta Therapeutics Investments, Inc., qui a achet茅 11,926,301 actions et a r茅gl茅 en esp猫ces 脿 cette date. La notification comprend la d茅claration standard selon laquelle la personne pour le compte de laquelle les titres doivent 锚tre vendus ne conna卯t aucune information d茅favorable importante non divulgu茅e.
Sarepta Therapeutics Investments, Inc., eine hundertprozentige Tochtergesellschaft von Sarepta Therapeutics, Inc., hat eine Form-144-Mitteilung eingereicht, die einen geplanten Verkauf von 9,265,312 Stammaktien des Emittenten 眉ber Jefferies LLC an der Nasdaq ank眉ndigt. Die Einreichung nennt einen aggregate market value von $185,213,586.88 und gibt die insgesamt ausstehenden Aktien mit 138,257,550 an. Das voraussichtliche Verkaufsdatum ist 08/13/2025.
Die Mitteilung besagt, dass diese Wertpapiere am 02/07/2025 durch eine Privatplatzierung vom Emittenten erworben wurden, wobei Sarepta Therapeutics Investments, Inc. 11,926,301 Aktien erworben und den Kauf an diesem Datum bar bezahlt hat. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass die Person, in deren Auftrag die Wertpapiere verkauft werden sollen, keine nicht offengelegten, wesentlichen nachteiligen Informationen kennt.
FAQ
What does ARWR's Form 144 notify investors about?
Who is the broker handling the proposed sale of ARWR shares?
What is the aggregate market value of the shares listed in the Form 144?
How many ARWR shares were outstanding according to the filing?
Who acquired the securities being sold and when were they acquired?
Does the filer attest to having any undisclosed material adverse information?
